Aytu Biopharma (AYTU) investor relations material

Business overview and product portfolio

• Focus on commercializing differentiated brands for central nervous system conditions, with a portfolio including the newly launched antidepressant EXXUA and mature ADHD brands ADZENYS and COTEMPLA, plus pediatric products.

• Portfolio generated $57–58 million in revenue for the 12 months ending June 30, 2026, with ADHD brands de-emphasized in favor of EXXUA.

• ADHD products remain resilient despite generic competition, supported by the in-house Aytu RxConnect patient access program.

• RxConnect ensures seamless, affordable access and high patient retention, leveraging data analytics for prescription-level insights and profitability tracking.

• Commercial infrastructure expanded to about 40 territories nationwide, with recent growth into western states and a flexible contract sales model to optimize salesforce performance.

EXXUA launch and market positioning

• EXXUA is a first-in-class 5-HT1A agonist for major depressive disorder, offering a novel mechanism distinct from SSRIs and demonstrating strong efficacy in multiple clinical studies.

• Product avoids common antidepressant side effects such as sexual dysfunction and weight gain, addressing key patient and physician concerns.

• Patented through at least 2030, EXXUA benefits from mandated government coverage for a significant portion of the depression market, supporting favorable reimbursement.

• Pricing power for EXXUA is five to seven times higher than ADHD products, with strong approval rates from both commercial and government payers.

• Clinical data show rapid and sustained symptom improvement, with early separation from placebo and a favorable tolerability profile.

Financial performance and outlook

• Fiscal 2026 net revenue was $57.6 million, reflecting contributions from ADHD, pediatric, and initial EXXUA sales, with revenue impacted by generic competition and launch investments.

• Adjusted EBITDA loss of $3.7 million in fiscal 2026, attributed to deliberate investments in EXXUA commercialization and salesforce expansion.

• Fiscal year ended with $26.3 million in cash and $61.8 million in current assets; total liabilities were $69.7 million, including $17 million in borrowings and a $14 million revolving credit facility.

• Strategy centers on leveraging commercial infrastructure, disciplined expense management, and maximizing EXXUA growth to drive improved financial performance.

• Balance sheet considered sufficient to support continued commercial expansion and long-term value creation.